We can’t show the full text here under this license.
EClinicalMedicine···
Safety and effects of weight loss medicines on body weight, heart health, and mental well-being in people with overweight or obesity
Updated
Abstract
A total of 154 randomized controlled trials involving 112,515 participants were analyzed.
- Tirzepatide resulted in the highest weight loss, with a mean difference of -11.69 kg.
- Tirzepatide also showed significant reductions in systolic and diastolic blood pressure.
- Both semaglutide and liraglutide lowered the risk of major adverse cardiovascular events.
- Naltrexone/bupropion was linked to an increased risk of elevated blood pressure.
- Phentermine/topiramate raised concerns about psychological side effects, including anxiety and irritability.
- No medication was associated with an increased risk of serious adverse events.
Simplified
BACKGROUND: Overweight and obesity pose serious health challenges for individuals and societies. This study aims to facilitate personalised treatment of obesity by summarising recent research on weight-loss pharmacotherapies, with a focus on their effects on weight reduction, cardiometabolic health, psychological outcomes, and adverse events.
METHODS: This systematic review and meta-analysis included searches of Web of Science, PubMed, and Cochrane Central Register of Controlled Trials from inception to June 8, 2024. Randomised controlled trials evaluating weight-loss pharmacotherapies approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for treating overweight or obesity were included. Primary outcomes included changes in body weight, cardiometabolic indicators, psychological outcomes, and adverse events. Summary data was extracted from published reports. Random-effects meta-analyses were used to calculate weighted mean differences (WMDs), risk ratios (RRs), and 95% confidence intervals (CI). The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was used to assess the certainty of evidence for each pooled analysis. PROSPERO registration: CRD42024547905.
FINDINGS: A total of 154 randomised controlled trials (n = 112,515 participants) were included. Tirzepatide had the greatest weight-loss effect (WMD -11.69, 95% CI -19.22 to -4.15; = 0.0024; I = 100.0%; moderate certainty), followed by semaglutide (-8.48, -12.68 to -4.27;< 0.0001; I = 100.0%; moderate certainty). Tirzepatide had the strongest antihypertensive effect on both systolic (WMD -5.74, -9.00 to -2.48; = 0.0006; I = 99.8%; moderate certainty) and diastolic blood pressure (WMD -2.91, -4.97 to -0.85; = 0.0056; I = 99.8%; moderate certainty) and best reduced triglycerides (WMD -0.77, -0.85 to -0.69;< 0.0001; I = 3.2%; high certainty), fasting glucose (WMD -3.06, -5.53 to -0.59; = 0.015; I = 100.0%; moderate certainty), insulin (WMD -4.91, -8.15 to -1.68; = 0.0029; I = 97.0%; moderate certainty), and glycated haemoglobin levels (WMD -1.27, -1.82 to -0.73;< 0.0001; I = 100.0%; moderate certainty). Semaglutide (RR 0.83, 0.74-0.92;< 0.0001; I = 0.0%; high certainty) and liraglutide (0.87, 0.79-0.96; = 0.0059; I = 0.0%; high certainty) reduced the risk of major adverse cardiovascular events (MACEs). However, all three medications were associated with adverse gastrointestinal effects. Naltrexone/bupropion increased the risk of elevated blood pressure (RR 1.72, 1.04-2.85; = 0.036; I = 0.0%; high certainty). Topiramate increased depression risk (RR 1.62, 1.14 to 2.30; = 0.0077; I = 0.0%; high certainty), and phentermine/topiramate raised concerns about anxiety (RR 1.91, 1.09 to 3.35; = 0.025; I = 29.5%; high certainty), sleep disorders (RR 1.55, 1.24-1.93;< 0.0001; I = 0.0%; high certainty), and irritability (RR 3.31, 1.69-6.47;< 0.0001; I = 0.0%; high certainty). No medication increased the risk of serious adverse events. P P P P P P P P P P P P P P P2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
INTERPRETATION: For weight reduction, tirzepatide is the top choice, followed by semaglutide. Considering cardiometabolic risk factors, tirzepatide shows the best blood pressure- and glucose-lowering benefits, while semaglutide and liraglutide reduce the risk of MACEs. Naltrexone/bupropion carries a risk of increased blood pressure. Phentermine/topiramate should be used with caution due to its higher risk of psychological side effects. Despite limitations related to study heterogeneity, these findings provide valuable insights for weight management strategies across diverse individuals.
FUNDING: National Natural Science Foundation of China, Leading Talents Program of Hunan Province, and Fundamental Research Funds for the Central Universities of Central South University.
Related papers
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 28 papers
systematic review
Jan '21
Long-term effects of weight-loss drugs in people with high blood pressure
cited by 16 papers
systematic review
Mar '16
Long-term effects of weight-loss drugs in people with high blood pressure
cited by 28 papers
systematic review
Dec '21
Drug treatments for adults with overweight and obesity: a combined analysis of clinical trials
top 1% journal
cited by 224 papers
systematic review
Jan '20
Comparing drug treatments for long-term plaque psoriasis
cited by 71 papers
systematic review
Dec '17
Comparing drug treatments for long-term plaque psoriasis using network analysis
cited by 63 papers
systematic review
Jun '16
Weight Loss and Side Effects Linked to Different Obesity Medicines: A Review and Analysis
top 1% journal
cited by 732 papers
systematic review